Profit outpacing revenue
Profit grew 34.1% while revenue grew 19.1%, so the company kept more of each rupee of revenue as profit.
Importance 63 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Profit grew 34.1% while revenue grew 19.1%, so the company kept more of each rupee of revenue as profit.
Importance 63 / 95 · growth
Revenue compounded at 20.8% a year over 4 years (₹3,931 → ₹8,373).
Importance 59 / 95 · growth
Net worth compounded at 14.4% a year over 4 years (₹6,282 → ₹10,747).
Importance 54 / 95 · financial health
Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.
Peer set used on this page: 3 hospital.
Revenue grew 13.5% a year over 4 years, from ₹1,729 cr in FY2022 to ₹2,874 cr in FY2026. Net profit grew 21.3% a year over the same period.
Profit grew 34.1% while revenue grew 19.1%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
Revenue compounded at 20.8% a year over 4 years (₹3,931 → ₹8,373).
Net profit grew 34.1% year on year (FY2025 → FY2026).
Revenue grew 19.1% year on year (FY2025 → FY2026).
In Q2 FY27 (Jul–Sep 2026), revenue was ₹2,569 cr (up 20.3% on the same quarter last year) and net profit ₹414 cr (down 15.6%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit declined 15.6% while revenue grew 20.3% vs the same quarter last year — a gap of 36.0 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
Q2 FY27 revenue was ₹2,569 cr, up 20.3% from ₹2,135 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 net profit was ₹414 cr, down 15.6% from ₹491 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 1,868 | +40.0% | 239 | −17.5% | 12.8% |
| Q4 FY25 | 1,910 | +34.2% | 319 | +26.8% | 16.7% |
| Q1 FY26 | 2,028 | +31.4% | 308 | +30.3% | 15.2% |
| Q2 FY26 | 2,135 | +25.1% | 491 | +74.3% | 23.0% |
| Q3 FY26 | 2,068 | +10.7% | 301 | +26.0% | 14.6% |
| Q4 FY26 | 2,143 | +12.2% | 342 | +7.3% | 16.0% |
| Q1 FY27 | 2,366 | +16.7% | 323 | +4.9% | 13.6% |
| Q2 FY27 | 2,569 | +20.3% | 414 | −15.6% | 16.1% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 39.1% in FY2026, against 31.6% in FY2022. ROE was 8.3% and ROCE 10.5% in FY2026.
ROE improved from 12.1% to 14.3% year on year.
Rule ROE_IMPROVED_YOY
Debt-to-equity was 0.09x in FY2026, against 0.07x in FY2022; interest coverage 24.57x. Operating cash flow was 0.70x net profit.
Net worth compounded at 14.4% a year over 4 years (₹6,282 → ₹10,747).
Rule NET_WORTH_COMPOUNDING
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.13×).
Free cash flow has been positive in 5 of the last 5 years.
Within its 3-company Hospital peer group, it ranks 2 of 3 on return on equity and 1 of 3 on EBITDA margin. Its P/E of 76.1 compares with a peer median of 58.7.
Ranked against 3 hospital (FY2026, consolidated). No peer-relative rule fired for this company.
MAXHEALTH · 1st of 3 · set median 17.3%
MAXHEALTH · 1st of 3 · set median 23.4%
MAXHEALTH · 2nd of 3 · set median 14.3%
MAXHEALTH · 3rd of 3 · set median 58.7×
On the trailing twelve months. Last full year: P/E 72.8× · P/S 12.3× · ROE 14.3%.
The share price is down 7.6% over 1 year, up 78.7% over 3 years (21.3% a year) and up 202% over 5 years (24.7% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 8.6% below its 52-week high.
Over 4 years profit (24.3% a year) and the stock (21.3% a year) compounded at roughly the same rate — but FY2022 profit (₹605) was well below the through-cycle level (~₹1,076), so this rate is inflated by the recovery from a low base.
Rule STOCK_TRACKED_EARNINGS · recovery
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,729 | 1,905 | 2,341 | 2,664 | 2,874 |
| Total income | 1,854 | 2,049 | 2,613 | 3,030 | 3,176 |
| EBITDA | 546 | 728 | 1,033 | 1,200 | 1,123 |
| Profit before tax | 403 | 563 | 865 | 947 | 924 |
| Net profit | 331 | 694 | 687 | 701 | 717 |
| EPS (₹) | 3.4 | 7.2 | 7.1 | 7.2 | 7.4 |
| Net worth | 6,309 | 7,042 | 7,681 | 8,289 | 8,941 |
| Total debt | 449 | 534 | 443 | 612 | 825 |
| Operating cash flow | 425 | 696 | 613 | 598 | 503 |
| Free cash flow | 59 | 579 | 156 | 345 | 153 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 10.2 | 22.9 | 13.8 | 7.9 |
| Profit growth YoY | — | 109.7 | -1.0 | 2.0 | 2.2 |
| Profitability | |||||
| EBITDA margin % | 31.6 | 38.2 | 44.1 | 45.0 | 39.1 |
| Net margin % | 17.9 | 33.9 | 26.3 | 23.1 | 22.6 |
| Return on equity % | 5.2 | 10.4 | 9.3 | 8.8 | 8.3 |
| Return on capital % | 6.6 | 8.6 | 11.7 | 12.6 | 10.5 |
| Leverage & cash | |||||
| Debt to equity | 0.07 | 0.08 | 0.06 | 0.07 | 0.09 |
| Cash flow ÷ profit | 1.28 | 1.00 | 0.89 | 0.85 | 0.70 |
| Current ratio | 2.36 | 3.26 | 2.01 | 1.42 | 1.61 |